Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06938841 · ClinicalTrials.gov registry record · NA

Maintenance rTMS for Depression (Maitr-De)

A NA study of Major Depressive Disorder and Treatment-Resistant Depression, sponsored by University of California, San Diego.

Recruiting
Registry status
NA
Development phase
75
Enrollment target
3
Study locations

NCT06938841 is a NA study of Major Depressive Disorder and Treatment-Resistant Depression that is actively recruiting participants, run by University of California, San Diego. The registered enrollment target is 75 participants, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (80% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06938841, a NA study of Major Depressive Disorder and Treatment-Resistant Depression, is actively recruiting participants, sponsored by University of California, San Diego.

RECRUITING
Registry status
NA
Development phase
75 participants
Enrollment target
3
Study locations

Study Summary

Repetitive transcranial magnetic stimulation (rTMS) has emerged as a promising intervention for treatment-resistant depression (TRD), yet substantial uncertainties persist regarding its efficacy as a maintenance treatment. This prospective study seeks to investigate the efficacy of maintenance rTMS in individuals with TRD who have previously responded to an acute course of rTMS. In the R61 phase of the study, we will recruit 75 participants across three study sites, the University of California San Diego, Weill Cornell Medicine, and Australian National University, into a double-blind, three-arm maintenance treatment trial. In this trial, participants will be randomized to receive either standard maintenance rTMS, clustered maintenance rTMS, or sham maintenance rTMS for a duration of 6 months. Our primary aim is to examine the efficacy of maintenance rTMS on sustaining connectivity between the dorsolateral prefrontal cortex (DLPFC) and subgenual cingulate cortex (SGC) measured through concurrent TMS and electroencephalography (TMS-EEG) at baseline and every six weeks throughout the 6-month treatment period. We will also assess changes in depressive symptom severity using clinical scales, including the Montgomery-Asberg Depression Rating Scale (MADRS) as a secondary outcome measure. It is hypothesized that stimulation with clustered maintenance rTMS will demonstrate superiority in sustaining DLPFC-SGC connectivity compared with standard maintenance rTMS and sham maintenance rTMS

Interventions

  • DEVICE Transcranial Magnetic Stimulation (TMS) - Standard maintenance rTMS:
  • DEVICE Transcranial Magnetic Stimulation (TMS) - Clustered maintenance rTMS:
  • DEVICE Transcranial Magnetic Stimulation (TMS) -- Sham maintenance rTMS

Study Locations (3)

California

  • University of California, San Diego - San Diego

New York

  • Weill Cornell Medicine - New York

Australian Capital Territory

  • Australian National University - Canberra

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2025-04-01
Est. Completion 2026-03-31
Phase NA

Sponsor

University of California, San Diego

775 total trials

What the Registry Record Tells You About NCT06938841

The ClinicalTrials.gov registry entry for NCT06938841 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (80% lower). The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Major Depressive Disorder appearing as the primary indexed condition, and to 3 interventions - of which Transcranial Magnetic Stimulation (TMS) - Standard maintenance rTMS: is the first listed.

NCT06938841 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, New York, Australian Capital Territory.

Frequently Asked Questions

What is clinical trial NCT06938841 about?

NCT06938841 is a clinical study titled "Maintenance rTMS for Depression (Maitr-De)". Repetitive transcranial magnetic stimulation (rTMS) has emerged as a promising intervention for treatment-resistant depression (TRD), yet substantial uncertainties persist regarding its efficacy as a maintenance treatment. This prospective study seeks to investigate the efficacy of maintenance rTMS ...

What is the current status of trial NCT06938841?

This trial is currently recruiting. It is a NA study. The enrollment target is 75 participants. The study started on 2025-04-01. Estimated completion is 2026-03-31.

What conditions does trial NCT06938841 study?

This clinical trial studies the following conditions: Major Depressive Disorder, Treatment-Resistant Depression.

What interventions are being tested in trial NCT06938841?

The interventions under investigation include: Transcranial Magnetic Stimulation (TMS) - Standard maintenance rTMS: (DEVICE), Transcranial Magnetic Stimulation (TMS) - Clustered maintenance rTMS: (DEVICE), Transcranial Magnetic Stimulation (TMS) -- Sham maintenance rTMS (DEVICE).

Who is sponsoring clinical trial NCT06938841?

This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06938841 being conducted?

This trial has 3 study locations across California, New York, Australian Capital Territory. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Major Depressive Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.